tiprankstipranks
Trending News
More News >
C-MER Eye Care Holdings Limited (HK:3309)
:3309
Hong Kong Market

C-MER Eye Care Holdings Limited (3309) AI Stock Analysis

Compare
1 Followers

Top Page

HK

C-MER Eye Care Holdings Limited

(3309)

Rating:54Neutral
Price Target:
HK$2.00
â–²(10.50%Upside)
The overall stock score of 54 reflects significant financial challenges, particularly in profitability and cash flow generation. While the company maintains a strong equity position, valuation metrics are weak due to negative earnings. Technical analysis shows moderate strength, but without clear positive trends. Immediate attention to financial performance is essential for future stability.

C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)

C-MER Eye Care Holdings Limited Business Overview & Revenue Model

Company DescriptionC-MER Eye Care Holdings Limited (3309) is a prominent eye care service provider based in Hong Kong. The company specializes in offering a comprehensive range of ophthalmic services which include treatments for cataracts, myopia, and other eye-related conditions. C-MER Eye Care is known for its advanced medical technology and highly skilled medical professionals, providing both surgical and non-surgical eye care solutions. The company operates through a network of eye clinics and hospitals, ensuring accessibility and quality care for patients across the region.
How the Company Makes MoneyC-MER Eye Care Holdings Limited generates revenue primarily through its extensive network of eye care clinics and hospitals. The company charges fees for various eye care services, including consultations, diagnostic tests, and surgical procedures such as cataract surgeries and refractive surgeries for vision correction. Additionally, they offer specialized treatments for myopia management and other ophthalmic conditions, which also contribute to their income. C-MER Eye Care's revenue model is further supported by partnerships with healthcare institutions and insurance providers, which help streamline patient referrals and payments. The company's investment in advanced medical technology and skilled personnel enhances its service offerings, thereby attracting a steady stream of patients and ensuring a significant market presence.

C-MER Eye Care Holdings Limited Financial Statement Overview

Summary
C-MER Eye Care Holdings Limited is experiencing financial challenges, evident from declining profitability and cash flow in 2024. The company has maintained a strong equity position and low leverage, but negative growth in revenue and net income raises concerns about future performance. Strengths include a conservative balance sheet, but immediate attention is needed on profitability and cash flow generation to support long-term stability.
Income Statement
55
Neutral
C-MER Eye Care Holdings Limited shows a mixed performance. The gross profit margin for 2024 is approximately 31.2%, indicating a decline from the previous year's 32.2%. The net profit margin turned negative in 2024 at -7.1%, down from 3.2% in 2023, reflecting a significant drop in profitability. Revenue growth is negative at -0.6% from 2023 to 2024. The EBIT margin is negative at -3.5% in 2024, down from 6.2% in 2023, and the EBITDA margin also decreased from 18.7% to 10.9%.
Balance Sheet
65
Positive
The company maintains a relatively stable equity position with an equity ratio of approximately 64.4% in 2024. The debt-to-equity ratio is 0.25, indicating a conservative leverage approach. However, return on equity has turned negative in 2024 at -7.7%, contrasting with a positive ROE of 3.4% in 2023, highlighting recent challenges in generating returns for shareholders.
Cash Flow
40
Negative
C-MER Eye Care Holdings Limited faced challenges with cash flow in 2024. Operating cash flow and free cash flow are reported as zero, which is concerning compared to the positive free cash flow of 245 million in 2023. This suggests potential issues with cash generation and management, impacting the company's ability to fund operations and growth.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.91B1.92B1.73B1.11B699.54M
Gross Profit527.62M618.96M365.34M309.44M163.65M
EBITDA209.18M359.88M194.31M177.80M126.69M
Net Income-135.16M62.00M-21.88M21.86M-6.25M
Balance Sheet
Total Assets2.72B2.75B2.90B1.96B1.63B
Cash, Cash Equivalents and Short-Term Investments467.25M557.42M698.51M442.36M553.93M
Total Debt437.79M362.99M452.49M471.69M244.97M
Total Liabilities830.24M755.35M903.45M618.63M331.98M
Stockholders Equity1.75B1.85B1.87B1.33B1.29B
Cash Flow
Free Cash Flow123.58M245.30M100.63M19.18M-233.39M
Operating Cash Flow283.12M361.15M191.86M148.41M104.03M
Investing Cash Flow-174.72M-245.37M-210.65M-392.72M-157.94M
Financing Cash Flow-194.92M-242.88M281.64M78.10M322.37M

C-MER Eye Care Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.81
Price Trends
50DMA
1.69
Positive
100DMA
1.70
Positive
200DMA
1.91
Negative
Market Momentum
MACD
0.03
Negative
RSI
63.61
Neutral
STOCH
89.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Positive. The current price of 1.81 is above the 20-day moving average (MA) of 1.74, above the 50-day MA of 1.69, and below the 200-day MA of 1.91, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 63.61 is Neutral, neither overbought nor oversold. The STOCH value of 89.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3309.

C-MER Eye Care Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$1.97B9.098.35%8.37%0.61%-15.89%
61
Neutral
HK$895.36M11.237.39%4.99%0.20%-36.95%
60
Neutral
HK$15.14B5.56-7.43%4.30%11.60%-21.06%
54
Neutral
HK$2.27B33.92-7.51%1.10%-0.56%-323.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:3309
C-MER Eye Care Holdings Limited
1.80
-0.85
-32.08%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.85
0.11
4.01%
HK:1846
EuroEyes International Eye Clinic Limited
2.73
-2.29
-45.62%

C-MER Eye Care Holdings Limited Corporate Events

C-MER Medical Holdings Announces Board Restructuring
May 30, 2025

C-MER Medical Holdings Limited has announced a new structure for its board of directors and committees, effective from June 1, 2025. This restructuring includes appointments of key individuals to various roles, which is expected to enhance the company’s governance and operational oversight, potentially impacting its strategic direction and stakeholder engagement positively.

C-MER Medical Holdings Announces Leadership Restructuring
May 23, 2025

C-MER Medical Holdings Limited announced significant changes in its leadership structure, with Dr. Lam Shun Chiu Dennis resigning as Chairman, Executive Director, and CEO to focus on clinical work and ophthalmic innovation. Despite his resignation, Dr. Lam will continue to contribute to the company as an ophthalmologist and senior advisor. The company also appointed Dr. Ko Wing Man as an independent non-executive director and vice chairman, and Mr. Li Ling Cheung Raymond as an independent non-executive director, enhancing its board with experienced professionals. These changes are expected to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.

C-MER Eye Care Holdings Reports Successful AGM with Strong Shareholder Support
May 19, 2025

C-MER Eye Care Holdings Limited, a company incorporated in the Cayman Islands, announced the successful passing of all resolutions at its Annual General Meeting held on 19 May 2025. The resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of executive directors, and granting of mandates for share repurchase and issuance. The results indicate strong shareholder support, with all resolutions receiving over 98% approval. This outcome reflects positively on the company’s governance and strategic direction, potentially reinforcing investor confidence.

C-MER Eye Care Holdings Announces AGM and Share Repurchase Plan
Apr 22, 2025

C-MER Eye Care Holdings Limited has announced its upcoming Annual General Meeting scheduled for May 19, 2025, where key agenda items include the approval of financial statements, the declaration of a final dividend, and the re-election of executive directors. Additionally, the company seeks shareholder approval to repurchase up to 10% of its issued shares, a move that could enhance shareholder value and reflect confidence in the company’s financial health.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 21, 2025